Our data suggest that the IPS has a predictive value in CYT-high melanoma patients who were to receive CTLA-4 and PD-1 inhibition therapy, and are in accordance with previous observations that patients with higher levels of tumor cytolytic activity, and expression of immune checkpoints, benefited more from the corresponding immune checkpoint blockers [42]. This evidence concerns the gene CTLA4 and melanoma.